A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CCA / cholangiocarcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 2171
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CCA  (>> Co-occurring Abbreviation)
Long Form:   cholangiocarcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 13‑cis‑retinoic acid inhibits the self‑renewal, migration, invasion and adhesion of cholangiocarcinoma cells. ---
2023 A phase II study of nab-paclitaxel and gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy (NACHO). DCR, ORR, OS, PFS, TRAEs
2023 Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma. ---
2023 Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review. ---
2023 ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation. CCK8, GO, GSEA, KEGG, RhoGAP
2023 Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. ---
2023 Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma. Hh, iCCA, PTCH1, Smo, TFs
2023 Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. ---
2023 Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma. NAC, ROS, STAT3
10  2023 Development and validation of a nomogram to predict cancer-specific survival with unresected cholangiocarcinoma undergoing external radiotherapy. C-index, CSS, DCA, SEER
11  2023 Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. FGFR, IDH
12  2023 Diagnosis of Cholangiocarcinoma. ERCP, EUS
13  2023 Distinct cholangiocarcinoma cell migration in 2D monolayer and 3D spheroid culture based on galectin-3 expression and localization. ---
14  2023 Effects of Health Literacy Promotion Programs for Preventing Opisthorchiasis and Cholangiocarcinoma: a Systematic Review and Meta-analysis. OV
15  2023 Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report and Literature Review of 890 Patients Affected by Uncommon Primary Liver Tumor Presentation. BDTT, HBV, HCC, RFA
16  2023 High Level of Serum Coiled-coil Domain Containing 25 (CCDC25) as a Diagnostic Marker for Cholangiocarcinoma But Not for Other Cancers. BC, CCDC25, CRC, GEPIA2, HC, HCC, HPA
17  2023 Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. CAF, FRGs
18  2023 Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA. DEGs, OS, WGCNA
19  2023 Imaging Features of Main Hepatic Resections: The Radiologist Challenging. CT, FLT, HCC, MRI, US
20  2023 Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis. CI, RR
21  2023 L-Fucose inhibits the progression of cholangiocarcinoma by causing microRNA-200b overexpression. FITC/PI, HUVECs, MAPK7, miR-200b
22  2023 Loss of tumor suppressor menin expression in high grade cholangiocarcinomas. IHC, TMA
23  2023 MC-GAT: multi-layer collaborative generative adversarial transformer for cholangiocarcinoma classification from hyperspectral pathological images. CNN, ViT
24  2023 Metabolic reprogramming and its clinical implication for liver cancer (HEP-22-1008). HCC, NAFLD
25  2023 Metabolic reprogramming and its clinical implication for liver cancer. HCC, NAFLD
26  2023 Microalga Chlorella sp. extract induced apoptotic cell death of cholangiocarcinoma via AKT/mTOR signaling pathway. ---
27  2023 Modelling metastatic colonization of cholangiocarcinoma organoids in decellularized lung and lymph nodes. CCAOs, ECM
28  2023 Mutational Impacts on the N and C Terminal Domains of the MUC5B Protein: A Transcriptomics and Structural Biology Study. MD
29  2023 Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study. AC, NAC, NCDB, OS, SA
30  2023 Overexpression of Insulin Receptor Substrate 1 (IRS1) Relates to Poor Prognosis and Promotes Proliferation, Stemness, Migration, and Oxidative Stress Resistance in Cholangiocarcinoma. IHC, IRS-1
31  2023 Pathology of Cholangiocarcinomas. iCCA
32  2023 Plasmon-Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis. FLEX, tEVs
33  2023 Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics. HB, HCC
34  2023 Racial Segregation Among Patients with Cholangiocarcinoma-Impact on Diagnosis, Treatment, and Outcomes. CI, CSS, IoD, RR
35  2023 Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. GC, HCC, ICI, MVI, SBRT, TACE, TARE, TKIs
36  2023 Study of the association between a MICA gene polymorphism and cholangiocarcinoma in Egyptian patients. NKG2D, NKG2DLs
37  2023 Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database. CI, eCCA, LN, SEER
38  2023 Tumor decellularization reveals proteomic and mechanical characteristics of the extracellular matrix of primary liver cancer. ECM, HCC
39  2023 Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. HCC, HPB, IO, PDA, TRM
40  2023 Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma. iCCA
41  2022 3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma. CSC, ECM, EMT, SF, SF-GHHs
42  2022 A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient. ---
43  2022 A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. CEUS, CT, HCC, MRI
44  2022 A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). DCR, OS, PFS, SBRT, TRR
45  2022 Aberrantly methylated-differentially expressed genes and related pathways in cholangiocarcinoma. GEO, Hyper-LGs, Hypo-HGs
46  2022 Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells. ---
47  2022 Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. alpha-SMA, TAA, TM, UPR
48  2022 Advances in Targeted Immunotherapy for Hepatobiliary Cancers. BTC, GBC, HCC
49  2022 Advances of cancer-associated fibroblasts in liver cancer. CAFs, HCC, TME
50  2022 Albendazole-induced autophagy blockade contributes to elevated apoptosis in cholangiocarcinoma cells through AMPK/mTOR activation. 3-MA, ABZ, CQ
51  2022 All-trans-retinoic acid induces RARB-dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells. ATRA, RAR, ROS
52  2022 An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. 8-IRDEGs, GEO, ImmPort, LASSO, RFS, TIDE, TIS
53  2022 An Innovative Test for the Rapid Detection of Specific IgG Antibodies in Human Whole-Blood for the Diagnosis of Opisthorchis viverrini Infection. ICT, WBS
54  2022 An Insight into Cholangiocarcinoma and Recent Advances in its Treatment. ---
55  2022 An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. CAR-T, HCC
56  2022 Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma. ANXA1, IHC
57  2022 Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2alpha, and HIF-1alpha. CK2
58  2022 Anti-metastatic Potential of Natural Triterpenoid Cucurbitacin B Against Cholangiocarcinoma Cells by Targeting Src Protein. ---
59  2022 Antibiotic-Resistant Bacteria Colonizing the Bile Duct Are Associated with Increased Morbidity and Mortality after Resection of Extrahepatic Cholangiocarcinoma. ASA, CHD, CI, OR
60  2022 Antitumor activity of T cells secreting alphaCD133-alphaCD3 bispecific T-cell engager against cholangiocarcinoma. alphaCD133-alphaCD3-ENG
61  2022 Antitumor Effects of Delta (9)-Tetrahydrocannabinol and Cannabinol on Cholangiocarcinoma Cells and Xenograft Mouse Models. CBN
62  2022 Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma. AL, OV/DMN
63  2022 Application of Urine and Copro Antigen Assays after Primary Infection and Drug Treatment in an Experimental Opisthorchiasis Animal Model. ---
64  2022 Arsenic-contaminated drinking water and cholangiocarcinoma. ECC, ICC
65  2022 Artificial intelligence and cholangiocarcinoma: Updates and prospects. AI
66  2022 Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. ---
67  2022 Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk population. aOR, CI, DBD, LM, US
68  2022 Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery. BTC, CT, NCDB, RT
69  2022 Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma. SCCA, SCCA1
70  2022 Bile-derived exosome noncoding RNAs as potential diagnostic and prognostic biomarkers for cholangiocarcinoma. ncRNA
71  2022 Biliverdin reductase B impairs cholangiocarcinoma cell motility by inhibiting the Notch/Snail signaling pathway. BLVRB, EMT
72  2022 Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. HCC
73  2022 Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy. ClC-3
74  2022 Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells. GRP78
75  2022 BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. ---
76  2022 Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy. alpha-SMA, CAFs
77  2022 Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways. CBD, CBG
78  2022 Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. PD-1
79  2022 Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. CPEs, HCC, MORV, VSV
80  2022 Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. ESRS
81  2022 Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles. ---
82  2022 Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation. CDM, HDACs
83  2022 Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. DNA vaccine, iCCA, PET, TAA
84  2022 Cholangiocarcinoma Attributed to Occupation: A Systematic Reviews. ---
85  2022 Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: A role for IL-17A. CCAOs, IL, PSC
86  2022 Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. ICD-11, LAD, MD, mOS
87  2022 Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. FA, FAO, NHC, Nicd1
88  2022 Cholangiocarcinoma protective factors in Greater Mekong Subregion: Critical issues for joint planning to sustainably solve regional public health problems. GMS, OV
89  2022 Cholangiocarcinoma: a review of the literature and future directions in therapy. EGFR, FGFR, IDH1
90  2022 Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy. ---
91  2022 Chromosomal aberrations, visualized using UroVysion fluorescence in-situ hybridization assay, can predict poor prognosis in formalin-fixed paraffin-embedded tissues of cholangiocarcinoma patients. FFPE, FISH, OS
92  2022 CHST4 might promote the malignancy of cholangiocarcinoma. DEGs, PPI, qPCR, STRING
93  2022 CircSETD3 (hsa_circ_0000567) inhibits proliferation and induces apoptosis in cholangiocarcinoma cells via downregulation of microRNA-421 expression. Bax, Bcl-2, BMF, circRNAs, miR, qRT-PCR
94  2022 Circular RNAs in cholangiocarcinoma. ceRNA, circRNAs, RBPs
95  2022 Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention. AD, BAs, HCC, IR, NAFLD, T2DM
96  2022 Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma. EV, HCC, mRNA, SNPs
97  2022 Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma. CSS, CTC, GBCA, RC
98  2022 Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis. circRNAs, HCC
99  2022 Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. ACRT, dCRT, nCRT
100  2022 Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma. ---